Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Current topics in vascular disorders]

K Ichikawa1, T Koike

  • 1Department of Medicine II, Hokkaido University School of Medicine.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|August 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A framework supporting the development of a Grid portal for analysis based on ROI.

Methods of information in medicine·2005
Same author

Methylation of the oestrogen receptor gene in non-neoplastic epithelium as a marker of colorectal neoplasia risk in longstanding and extensive ulcerative colitis.

Gut·2005
Same author

A kinetic study of enhancing effect by phenolic compounds on the hydroxyl radical generation during ozonation.

Water science and technology : a journal of the International Association on Water Pollution Research·2004
Same author

Development of colonic neoplasia in p53 deficient mice with experimental colitis induced by dextran sulphate sodium.

Gut·2004
Same author

An association study of asthma and total serum immunoglobin E levels for Toll-like receptor polymorphisms in a Japanese population.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2004
Same author

Genetic evolution of alpha fetoprotein producing gastric cancer.

Journal of clinical pathology·2003
Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019
See all related articles

Antiphospholipid antibodies (aPL) are linked to blood clots, pregnancy loss, and low platelets, defining antiphospholipid syndrome (APS). Treatments include aspirin, warfarin, heparin, and intensive therapies for catastrophic APS.

Area of Science:

  • Immunology
  • Hematology
  • Rheumatology

Context:

  • Antiphospholipid antibodies (aPL), including anticardiolipin antibodies (aCL) and lupus anticoagulant (LA), are increasingly recognized for their association with significant clinical complications.
  • These complications include thromboembolism, recurrent fetal loss, and thrombocytopenia, collectively forming the basis for diagnosing antiphospholipid syndrome (APS).

Purpose:

  • To elucidate the immunological targets and clinical classifications of antiphospholipid syndrome (APS).
  • To outline the current therapeutic strategies for managing APS and its severe manifestations.

Summary:

  • Antiphospholipid antibodies (aPL), specifically aCL and LA, are implicated in thromboembolic events, fetal loss, and thrombocytopenia.
  • Patients with these clinical features and aPL are diagnosed with APS; those without other autoimmune diseases have primary APS.

Related Experiment Videos

  • aCL targets beta 2-glycoprotein I bound to cardiolipin, while LA involves prothrombin and anionic phospholipids.

    • Impact:

    • Understanding the specific antibody targets (e.g., beta 2-glycoprotein I, prothrombin) aids in refining diagnostic criteria and understanding pathogenesis.
    • Standard treatments like aspirin, warfarin, and heparin are available for APS, with intensive options for catastrophic APS.
    • Recognition of catastrophic APS necessitates aggressive management including corticosteroids, immunosuppression, and plasmapheresis.